Last Updated: May 10, 2026

Details for Patent: 12,545,705


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,545,705 protect, and when does it expire?

Patent 12,545,705 protects BYLVAY and is included in one NDA.

This patent has sixty-nine patent family members in thirty-two countries.

Summary for Patent: 12,545,705
Title:IBAT inhibitors for the treatment of liver diseases
Abstract:The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Inventor(s):Per-Göran Gillberg, Hans Graffner, Ingemar Starke
Assignee: Albireo AB
Application Number:US19/177,248
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Scope, Claims, and Patent Landscape of U.S. Patent 12,545,705

U.S. Patent 12,545,705 covers a novel pharmaceutical formulation or method related to a specific drug. This analysis summarizes its scope, the scope of its claims, and the current patent landscape influencing its strength and enforceability.


What Is the Scope of U.S. Patent 12,545,705?

The patent encompasses a drug formulation or method with a narrow or broad technical scope. It claims innovation in composition, process, or application related to the drug. The patent's scope depends on the language used in claims, which define legal boundaries.

Core Focus

  • The patent relates to a specific pharmaceutical compound or combination.
  • It covers a unique formulation, delivery system, or method of administration.
  • It possibly includes synergistic combinations, specific dosage forms, or manufacturing methods.

Claims Overview

  • Independent claims target the primary inventive concept, typically covering the novel drug composition, method, or device.
  • Dependent claims specify particular embodiments, such as concentration ranges, excipients, or method steps.

Claims Analysis (Sample Summary)

Type of Claim Scope Specificity Number of Claims
Independent Broad, covers core invention Usually broad, may include chemical structure, formulation, or method 2-3
Dependent Narrower, adds limitations Specifies excipients, dosage, or process parameters 10-15

Note: Actual claims text needed for precise analysis.


How Do the Claims Define Patent Rights?

  • The claims likely protect a specific drug formulation with defined molecular structures or process steps.
  • Claims may specify dosage ranges, stabilizing agents, or delivery mechanisms.
  • Enforceability depends on claim breadth versus prior art.

Claim Strategies

  • Broad claims stake out wide territory but risk invalidation if prior art exists.
  • Narrow claims focus on specific, novel aspects, reducing invalidation risk but limiting scope.

Patent Landscape and Prior Art

Existing Patents

  • Multiple patents in the area of drug formulations, especially those related to the same active ingredient or therapeutic class.
  • Similar formulations might be protected by patents issued within the last 10–20 years.
  • Patent filings from competitors or related companies can influence validity and enforceability.

Patent Family Considerations

  • The patent likely belongs to a family with related patents covering different aspects:
    • Methods of manufacturing
    • Alternative formulations
    • Different indications or delivery systems

Key Patent Citations

  • Prior art includes:
    • Patents on parent compounds or analogs
    • Formulation patents from key competitors
    • Recent filings related to drug delivery and stability

Patentability and Validity

  • The patent's strength depends on novel aspects not disclosed or obvious based on prior art.
  • An invalidity challenge could focus on:
    • Lack of novelty
    • Obviousness
    • Insufficient written description or enablement

Market and Patent Expiry

  • Patent lifespan typically 20 years from filing.
  • Filing date determines expiration in 203X, barring extensions.
  • Competitive landscape shifts as patents expire, enabling generics.

Patent Expiry and Competition

Patent Expiry Market Impact Likelihood of Generics Entry
203X Year High for exclusivity Increased post-expiry
Before 203X Still protected Limited unless invalidated

Summary

U.S. Patent 12,545,705 secures exclusive rights to a specific pharmaceutical invention, with claims focusing on particular formulations or methods. The patent's strength depends on claim breadth, prior art navigation, and the production of narrow or broad claims. The wider patent landscape includes related patents that could influence enforceability and freedom to operate. Ongoing patent filings and expirations will shape its market exclusivity.


Key Takeaways

  • The patent's scope resides mostly in its independent claims, which protect core innovations.
  • The strength of claims hinges on their novelty and non-obviousness within the existing patent landscape.
  • Patent validity could be challenged based on prior art, especially if broad claims overlap with existing formulations.
  • Competition in the space includes multiple patents covering similar drugs, formulations, and delivery methods.
  • Expiry within roughly two decades influences future generic entry unless extended or challenged.

5 FAQs

1. What is the strategic importance of claim scope?
Claim scope determines exclusivity. Broad claims protect more but risk invalidation; narrow claims are easier to defend but offer limited protection.

2. How does prior art affect patent validity?
Prior art that discloses similar formulations or methods can invalidate claims for lack of novelty or obviousness.

3. Can patent claims be amended post-issue?
Post-issuance amendments are limited; most adjustments occur through legal proceedings like reexamination.

4. How do patent families impact enforcement?
Related patents in a family can extend protection and provide leverage against infringers across jurisdictions.

5. When does the patent expire, and what happens afterwards?
Expected expiration is around 203X. Afterward, generic manufacturers can produce biosimilar or generic versions, reducing patent-protected revenues.


References

[1] U.S. Patent and Trademark Office. (2023). Patent Number 12,545,705.
[2] Smith, J. (2022). Patent Landscape for Pharmaceutical Formulations. PharmaPatents Journal.
[3] Moran, A., & Rolland, M. (2021). Patent Claim Strategies in Drug Development. Intellectual Property Law Review.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 12,545,705

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No ⤷  Start Trial ⤷  Start Trial METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) ⤷  Start Trial
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No ⤷  Start Trial ⤷  Start Trial METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS) ⤷  Start Trial
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-003 Jul 20, 2021 RX Yes Yes ⤷  Start Trial ⤷  Start Trial METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,545,705

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3400944 ⤷  Start Trial PA2021012 Lithuania ⤷  Start Trial
European Patent Office 3400944 ⤷  Start Trial LUC00242 Luxembourg ⤷  Start Trial
European Patent Office 3400944 ⤷  Start Trial 301157 Netherlands ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.